David Clapham
Overview
Explore the profile of David Clapham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salunke S, Agrawal A, Walsh J, Nunn A, Hughes K, Kuehl P, et al.
Eur J Pharm Biopharm
. 2024 Aug;
203:114458.
PMID: 39159869
Excipients are often the major component of the formulation that critically affect the dosage form, manufacturing process, product performance, stability and safety. They exert different roles and functions in a...
2.
Agrawal A, Salunke S, Rumondor A, Thompson K, Caivano G, Walsh J, et al.
Eur J Pharm Biopharm
. 2024 Aug;
203:114447.
PMID: 39122051
It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The...
3.
Clapham D, Belissa E, Inghelbrecht S, Pense-Lheritier A, Ruiz F, Sheehan L, et al.
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765288
It is well established that treatment regime compliance is linked to the acceptability of a pharmaceutical formulation, and hence also to therapeutic outcomes. To that end, acceptability must be assessed...
4.
Ruiz F, Nunn A, Gill A, Clapham D, Fotaki N, Salunke S, et al.
Eur J Pharm Biopharm
. 2023 Apr;
188:265-270.
PMID: 37100092
The EMA defines acceptability as "the overall ability and willingness of the patient to use, and their caregiver to administer, the medicine as intended" [1]. This paper seeks to outline...
5.
Clapham D, Bennett J, Cram A, Discihnger A, Inghelbrecht S, Pense-Lheritier A, et al.
J Pharm Sci
. 2021 Sep;
111(5):1219-1223.
PMID: 34499899
Palatability is amongst the most important determinants of whether or not a child will take a medicine. In order to increase concordance with treatment regimens it is often necessary to...
6.
Salunke S, Clapham D, Agrawal A, Hughes K, Nunn T
Eur J Pharm Biopharm
. 2021 Jan;
160:77-81.
PMID: 33400989
The development of age appropriate formulations for the paediatric population has become one of the key areas of focus for the pharmaceutical industry - with a subsequent influence on excipient...
7.
Tuleu C, Hughes D, Clapham D, Vallet T, Ruiz F
Drug Discov Today
. 2020 Nov;
26(2):329-343.
PMID: 33217597
Optimum use of generic products would require equivalence, not only in terms of quality, safety, and efficacy in clinical studies, but also patient acceptability to not jeopardize treatment success because...
8.
VON Arnold S, Zhu T, Larsson E, Uddenberg D, Clapham D
Methods Mol Biol
. 2020 Jan;
2122:241-255.
PMID: 31975307
Somatic embryogenesis in Norway spruce combined with reverse genetics can be used as a model to study the regulation of embryo development in conifers. The somatic embryo system includes a...
9.
OBrien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, et al.
Int J Mol Sci
. 2019 Jun;
20(11).
PMID: 31159216
The development of age-appropriate formulations should focus on dosage forms that can deliver variable yet accurate doses that are safe and acceptable to the child, are matched to his/her development...
10.
Egertsdotter U, Ahmad I, Clapham D
Front Plant Sci
. 2019 Mar;
10:109.
PMID: 30833951
For large scale production of clonal plants, somatic embryogenesis (SE) has many advantages over other clonal propagation methods such as the rooting of cuttings. In particular, the SE process is...